Srikiran Pothamsetty, MD
Gastroenterology · Orlando, FLNPI 1821190562
Payments from drug & device makers
Across 122 payments — averaging $479.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Genentech, Inc.$32K
- Biotronik Inc.$20K
- AbbVie$5K
- Johnson & Johnson$191
- Celltrion USA Inc.$166
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$162
- plus $1K from 26 others
What the payments were for
- Consulting fees$240%
- Speaking & faculty fees$4,40016%
- Grants$20,00075%
- Food & beverage$2,3099%
- Education$470%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Genentech, Inc. | 6 | $31,762 |
| Biotronik Inc. | 1 | $20,000 |
| AbbVie(2 entities) | 32 | $4,901 |
| Johnson & Johnson | 7 | $191 |
| Celltrion USA Inc. | 7 | $166 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 10 | $162 |
| Ardelyx, Inc. | 7 | $131 |
| Ironwood Pharmaceuticals, Inc | 2 | $103 |
| Intercept Pharmaceuticals, Inc. | 4 | $93 |
| Merck | 4 | $92 |
| Olympus America Inc. | 1 | $91 |
| Redhill Biopharma Inc. | 4 | $89 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $69 |
| Regeneron Healthcare Solutions, Inc. | 3 | $69 |
| Amgen | 2 | $61 |
| QOL Medical, LLC | 3 | $57 |
| Gilead | 4 | $55 |
| Covidien LP | 4 | $54 |
| Lilly USA, LLC | 2 | $51 |
| ASD Specialty Healthcare, LLC | 1 | $50 |
| Phathom Pharmaceuticals, Inc. | 2 | $38 |
| Vivus LLC | 2 | $36 |
| Evoke Pharma, Inc. | 2 | $31 |
| Novo Nordisk | 1 | $30 |
| Aimmune Therapeutics, Inc. | 1 | $26 |
| Braintree Laboratories, Inc. | 1 | $23 |
| Alnylam Pharmaceuticals Inc. | 1 | $22 |
| Sanofi | 1 | $21 |
| Bristol Myers Squibb | 1 | $19 |
| Medtronic | 1 | $18 |
| Nestle Healthcare Nutrition Inc. | 1 | $18 |
| Phadia US Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LINZESS$4,400
How this compares
$58,541 in reported general payments places this provider in the 85th percentile of 1,388 gastroenterology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LinzessLinaclotide | 224 | $226,528 |
| CreonLipase/Protease/Amylase | 30 | $101,299 |
| IbsrelaTenapanor Hcl | 33 | $56,261 |
| Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates | 555 | $35,142 |
| Mesalamine | 68 | $33,665 |
| ZenpepLipase/Protease/Amylase | 11 | $33,623 |
| ClenpiqSod Picosulf/Mag Ox/Citric Ac | 182 | $30,455 |
| MotegrityPrucalopride Succinate | 34 | $28,118 |
| VemlidyTenofovir Alafenamide | 16 | $22,696 |
| TrulancePlecanatide | 22 | $17,570 |
| MovantikNaloxegol Oxalate | 14 | $7,194 |
| Omeprazole | 629 | $6,843 |
| Famotidine | 466 | $5,734 |
| Gavilyte-GPeg3350/Sod Sulf,bicarb,cl/Kcl | 238 | $3,721 |
| Gavilyte-CPeg3350/Sod Sulf,bicarb,cl/Kcl | 199 | $3,697 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLinzess, Creon | $4,901 | $327,827254 claims |
| Ardelyx, Inc.Ibsrela | $131 | $56,26133 claims |
| Aimmune Therapeutics, Inc.Zenpep | $26 | $33,62311 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Motegrity | $69 | $28,11834 claims |
| GileadVemlidy | $55 | $22,69616 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCTrulance | $162 | $17,57022 claims |
| Redhill Biopharma Inc.Movantik | $89 | $7,19414 claims |
| Braintree Laboratories, Inc.Sutab | $23 | $2,11413 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,388 gastroenterology providers in Florida.
Other gastroenterology in Orlando
- Henry LevineOrlando$3.4M
- Samuel GidayOrlando$2.1M
- Jennifer Seminerio-DiehlOrlando$1.7M
- Huy TranOrlando$1.2M
- Jason KorenblitOrlando$666K
- Saurabh AgrawalOrlando$584K
- Howard SchwartzTavernier$38.8M
- Guy NeffSarasota$17.6M
- Syed LateefClermont$6.4M
- Jeffrey SchneiderCoral Springs$6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.